Introduction: This pilot trial will inform the design and methods of a future full-scale random-
Musculoskeletal (MSK) pain is reported by 66% of older adults (Thomas, Peat, Harris, Wilkie, & Croft, 2004) . Patients with chronic MSK pain have reduced physical activity (van den Berg-Emons, Schasfoort, Vos, Bussmann, & Stam, 2007) and pain is an important predictor of physical inactivity (Plooij, van der Spek, & Scherder, 2012) .
Physical activity reduces pain, improves quality of life and reduces the risk of chronic illness in those with MSK pain (Der Ananian et al., 2006) . In older people, walking reduces pain and the risk of joint replacement (Ageberg et al., 2012) . Interventions to support increased walking in older people with chronic MSK pain are appropriate, although the mechanisms to achieve this remain unclear. Developing such interventions is challenging, as they need to address pain-related factors such as fear of injury (Cook, Brawer, & Vowles, 2006) and fear of falling (Hubscher, Vogt, Schmidt, Fink, & Banzer, 2010) . A recent systematic review concluded that walking-based exercise can be recommended for individuals with chronic MSK pain, but further, robustly designed research with longerterm follow-up is required (O'Connor et al., 2015) .
Whether these review findings are transferable to the older population is unclear. In older people, restricted mobility, limited time, transportation and finance are barriers to participating in physical activity interventions. Alternative methods of delivering support to these individuals (e.g. telephone, email, text) could encourage them to take part and adhere to an intervention. A recent walking intervention for older adults with knee osteoarthritis demonstrated increased adherence when supported according to preference (Loew et al., 2017) ; therefore, it appears that choice is of importance to this population. Interventions that also emphasize the evidence-based, dose-response nature of increasing individual physical activity (i.e.
"some is good, more is better", irrespective of an individual's starting point) may be beneficial (Ambrose & Golightly, 2015) .
The National Institute for Health and Care Excellence (NICE) concluded in their behaviour change guideline that interventions should incorporate a range of behavioural strategies, including goal setting, selfmonitoring, self-efficacy, support and relapse prevention (National Institute for Health and Care Excellence, 2007) . In order to maximize physical activity behaviour change, it is important that physical activity interventions are successful at promoting self-regulatory and volitional skills (drawing on intentions as a vehicle to change) as well as traditional motivational components, such as self-efficacy (Sniehotta, Scholz, & Schwarzer, 2006) .
To facilitate roll-out in primary care, interventions should be acceptable and feasible to patients, intervention deliverers and the setting in which they will be undertaken. Interventions also need to be cost-effective; selection of the intervention deliverer is vital. In primary care, healthcare assistants (HCAs) are increasingly expected to provide brief behaviour change advice on physical activity, weight management, alcohol consumption and smoking cessation during NHS health checks, and therefore may be suitable deliverers of a walking intervention for older adults with chronic MSK pain, given appropriate training.
| AIMS AND OBJECTIVES
The aims of the pilot trial are to test the design and methods of a future full-scale randomized controlled trial (RCT) and examine the feasibility, acceptability and fidelity -the degree to which the intervention is delivered as intended (Gearing et al., 2011 ) -of the HCA-supported Increasing Physical activity in Older People with chronic Pain (iPOPP) intervention to promote walking in older adults with chronic MSK pain in a primary care setting.
The objectives of the pilot trial are:
1. To determine the response rate of general practices to participate in the pilot trial.
2. To assess the feasibility and acceptability of the HCA-supported iPOPP intervention, with a particular focus on the HCAs' experiences of delivering the intervention, and participants' experiences of receiving the intervention.
3. To determine whether HCAs can be recruited, trained and retained to deliver the iPOPP intervention for the pilot trial.
4. To assess fidelity of the HCA-supported iPOPP intervention delivery.
5. To estimate overall participant recruitment to the trial.
6. To estimate the short-term follow-up rate at 12 weeks across trial arms and per treatment arm.
7. To examine the completion rates of the self-reported outcome measures (for primary and secondary outcome measures).
8. To estimate the parameters needed for a realistic sample size calculation for a larger RCT.
9. To assess the feasibility and quality of collecting and analysing objective physical activity data as the primary outcome data for a future full-scale trial, using accelerometers.
10. To integrate data analysis and findings from the quantitative and qualitative evaluations, in order to identify changes required to the trial design and intervention components ahead of a full-scale trial.
| METHODS

| Trial design and setting
The Standard Protocol Items for Randomized Trials (SPIRIT) recommendations were followed in preparing this protocol (see Appendix 1) (Chan et al., 2013) . This is an individually randomized, multicentre, three-parallel-arm pilot RCT recruiting 150 participants from four general practices across Cheshire and the West Midlands, UK.
General practitioner (GP) practices are eligible to take part if they use the clinical operating system EMIS Web (a clinical electronic computer system for delivering healthcare which allows healthcare professionals to record, share and use vital patient information), and are willing to allow their employed HCAs to be trained and to deliver the HCA-supported intervention. General practice participation will be formalized through written service level agreements.
| Trial population
Adults aged 65 years and over who have consulted at their general practice in the last 12 months for MSK pain in one or more of the index sites (foot, knee, hip, back, shoulder or neck) and have had their pain for ≥3 months will be recruited to the trial. The full pilot trial eligibility criteria are listed in Box 1. ). In addition, the computerized record screening protocol will take into account aspects of the exclusion criteria where possible (e.g. those in residential or nursing home accommodation or those with congestive heart failure). From each practice, a GP will be given the opportunity to review the list generated and exclude those patients whom they consider inappropriate to be invited into the trial, according to the trial exclusion criteria. CRN staff will then administer an initial mailing phase in the form of a brief chronic pain screening survey, to identify and screen potentially eligible participants.
The screening survey will assess the eligibility criteria, enquire about pain location and duration, determine the patient's Chronic Pain Grade classification (von Korff et al., 1992) and confirm access to a telephone (to enable further eligibility checking by a research nurse and facilitate consent). Patients will be eligible to participate in the trial if they have a Chronic Pain Grade classification of between 2 and 4 (i.e. clinically significant mean levels of pain and functional difficulty) (Foster et al., 2014) .
Patients will return their screening survey to the Arthritis Research UK Primary Care Centre and only those who are eligible and consent to further contact will form the sample that are sent information about the iPOPP trial.
| Approach and recruitment to the iPOPP trial
Those who meet the eligibility criteria and who agree to further contact will be posted an iPOPP trial pack (a cover letter, a patient information sheet, a baseline questionnaire and a freepost return envelope). Patients will then be contacted by a CRN nurse by telephone to confirm eligibility and willingness to participant within 10 working days. Those who wish to take part in the trial will be asked to sign and date the written consent form (see Appendix 2) and return it, along with the completed baseline questionnaire, to the study team in a pre-paid envelope. On receipt of the written informed consent form and baseline questionnaire, each participant will be sent an accelerometer in the post for baseline data collection. Once accelerometry data collection is complete (7 days) and the accelerometer is returned to the research centre, participants will be randomized. Figure 1 summarizes the participant recruitment for the iPOPP trial.
| Randomization
Participants will be randomized to one of the three interventions using third-party computerized randomization supported by Keele Clinical Trials Unit (CTU). To ensure that participants at each general practice have an equal chance of receiving any of the interventions, participants will be individually randomized using random permuted blocks, stratified by general practice.
The GP of each participant will be sent a letter to confirm that their patient is taking part in the trial, unless the participant does not provide consent for this.
| Allocation concealment, blinding and selection bias
A CRN nurse blind to subsequent treatment allocation will obtain informed consent. Selection bias at recruitment will be avoided by separating the processes of determining patient eligibility and intervention allocation. The trial database will be password protected, to ensure that the trial statistician and study personnel involved in the questionnaire and accelerometry data collection remain blind to treatment allocation. Allocation concealment and blinding is not possible for the participants or HCAs; however, the HCAs will deliver only one of the three trial interventions. Data entry, coding, security, storage and management will follow the standard operating procedures at Keele CTU.
| The interventions
Each of the three interventions are detailed below:
1. Usual care: Participants randomized to this intervention will be sent some high-quality written information in the form of the pain toolkit (http://www.paintoolkit.org) in the post by the study team, and will continue to be managed via usual care. The pain toolkit is a simple booklet that provides participants with tips and advice to support them in managing their pain. Usual primary care management normally consists of a patient consulting their GP or practice nurse for their pain, and may include advice and education, the prescription of medication and referrals to other appropriate services, such as physiotherapy, podiatry or occupational therapy.
2. Usual care plus pedometer: Participants randomized to this intervention will continue with their usual care, and in addition will receive in the post a pedometer, a pedometer user guide based on the NICE guidance on promoting walking (National 3. iPOPP walking intervention: When a participant is randomized to this intervention, the trial coordinator will pass on contact details to the relevant trained HCA. The HCA will then contact the participant to arrange their first consultation. The aim of this intervention is to initiate and support adherence to a walking plan. In brief, participants allocated to this intervention arm will be offered an initial appointment for a face-to-face consultation at their general practice with a trained HCA. At this first consultation, participants will receive a pedometer, the user guide and a walking diary plus a copy of the pain toolkit. The consultation (approximately 30 min) will include two components. The motivational stage will draw on motivational interviewing techniques, to prompt the patient to make self-motivating statements about walking behaviour. Then, in the action planning stage, volitional techniques will be used to facilitate realistic walking goals, to help to translate intentions into practice (e.g. setting specific, measurable, achievable, realistic, time-related [SMART] goals and drawing on the use of the pedometer). Participants will be encouraged to identify places (e.g. the local park, their home) where they can accumulate steps over the course of a day.
Important barriers to walking specific to the individual, such as pain-related fear of movement, will be addressed. Participants will receive a second consultation about 2 weeks later (approximately 30 min) either face to face or via telephone (depending on participant preference), consisting of a review of progress since the first consultation, positive feedback in relation to effort and achievement, possible revision of goals set, and relapse prevention strategies (e.g. support from friends/family, identifying a walking "buddy"). Participants will then receive eight weekly motivational prompts, which will be in the form of a postcard, email or text (dependent on patient preference).
Participants allocated to this intervention arm will also continue to access usual care (as described above). Each HCA will use a case report form (CRF) to record what happened during the two intervention consultations, how they were delivered (face to face or telephone), the dates of the consultations and the agreed method for the eight weekly motivational prompts (postcard, text or email). This information will be sent by the HCA back to the study team and logged on the trial database. The start of the weekly prompts will be initiated by the trial database.
| DEVELOPMENT OF THE HCA TRAINING
The development and content of the HCA-supported iPOPP intervention training will be reported elsewhere. In brief, the development of the HCA training programme will, in line with previous research, consist of four phases (French, Stevenson, & Michie, 2012; Healey et al., 2015; Porcheret et al., 2014) : (i) defining the content; (ii) selecting the behaviour change techniques; (iii) deciding on the style of delivery;
and (iv) addressing local practicalities. It is anticipated that at least one HCA will be trained to deliver the HCA-supported iPOPP intervention per practice and that the training will take place in a group setting over 2 days, 1 week apart, to allow the HCAs to absorb and reflect on what they have learnt, re-read intervention materials and complete "homework" before further review training. All HCA time taken to attend the training and deliver the intervention will be reimbursed to the general practice that employs them. All HCAs that attend the training will be asked to complete a pre-and post-training evaluation questionnaire, focused on assessing knowledge and confidence to deliver the iPOPP intervention.
| OUTCOMES
In order to achieve the aims and objectives set out for this pilot trial, a theoretically informed mixed-methods approach, including semistructured interviews, audio recordings of the HCA consultations, participant self-reported questionnaires, CRFs, and accelerometry data collection, will be undertaken. These methods of data collection will help to inform the design and methods of a future full-scale RCT and examine the feasibility, acceptability and fidelity of the HCAsupported intervention (iPOPP) in a primary care setting.
| Qualitative data collection
Audio recordings of a sample of HCA consultations (including both first and second consultations) and semi-structured interviews with all HCAs and a sample of participants will form the basis of the qualitative data collection.
| Audio-recording of the HCA-supported iPOPP intervention consultations
A sample of the first and second HCA consultations will be digitally audio-recorded, with HCA and participant consent. These audio recordings will focus on the fidelity of the iPOPP intervention delivery -for example, which elements of this intervention the HCAs used, whether the training was reflected in HCA behaviour and whether there are any gaps in intervention delivery.
Each HCA trained (n = 6) to deliver the iPOPP intervention will be asked to record a total of six consultations, with three participants (ideally three first and three second consultations). The team will therefore have a minimum of 36 recorded consultations. A digital recorder will be used, and switched on by the HCA at the start of the consultation.
Fully informed consent from the participant for the recording of both consultations with the HCA will be obtained by a member of the study team.
| Semi-structured interviews
Semi-structured interviews will be conducted with a sample of participants (pedometer and iPOPP interventions only) and all trained HCAs.
The interviews with participants will explore the acceptability and credibility of the pedometer and iPOPP interventions, whether walking has been continued, barriers and facilitators to maintaining or increasing walking, and prior experience of consulting with HCAs (iPOPP intervention only).
The interviews with the HCAs will explore how the training developed their knowledge and skills to enable them to deliver the intervention, how the training could be improved and the factors that helped or hindered the implementation and delivery of the intervention to the target population.
HCAs
All of the HCAs (n = 6) trained to deliver the iPOPP intervention will be invited to participate in individual telephone or face-to-face semistructured interviews at the end of the intervention period. A topic guide will stimulate dialogue in the interview and allow an exploration of the acceptability and operationalizing of the training and the iPOPP intervention.
Trial participants
A sample of participants across the four practices, from the pedometer and iPOPP interventions only, will be invited to participate in a semistructured interview after the 12-week follow-up data collection is complete. We will specifically sample participants who completed and dropped out of the iPOPP intervention, to explore reasons for completion and drop-out. A sample will be selected from the pedometer intervention purposively, based on practice, age and gender, to ensure a broad range of participants. Approximately 10-15 participants per intervention will be interviewed; data collection will be continued until category saturation is achieved in each group.
All interviews and audio recordings of the iPOPP intervention will be digitally recorded, with consent, and will be professionally transcribed verbatim. This will form the data for analysis.
| Quantitative data collection
Accelerometry data, self-reported questionnaires, and individual CRFs (iPOPP intervention only) will form the basis of the qualitative data collection.
| Accelerometers
This trial will primarily use these objective physical activity monitors to estimate levels of physical activity via average daily step count.
Number of counts per minute, time spent sedentary, time spent in light, moderate and vigorous physical activity, and proportions of people who meet guideline levels of physical activity will also be estimated (Department of Health., 2011; Foster et al., 2014; Lee et al., 2015) . This pilot trial is not powered to detect clinically relevant differences between the interventions in walking, and these data will not be used as criteria for progression to a full trial. However, we will collect data on the feasibility of using accelerometers as the primary outcome in our target population for a full-scale trial. The waist-worn triaxial accelerometer units (wGT3X-BT monitor, Actigraph, Pensacola, FL, USA) will be pre-programmed and posted out to the participants with full instructions, once consent to the trial is received but prior to randomization, and again at the 12-week follow-up. Participants will be asked to wear the unit for 7 consecutive days on their waist during waking hours, and then to post the unit back to the research centre, where the data collected will be downloaded and analysed if participants have worn the accelerometer on at least 5 days, for 10 h or more each day (assuming that consecutive runs of zero count for 60 min or more are "non-wear") (Foster et al., 2014) . To maximize response rates, participants will receive up to two reminder telephone calls and a reminder postcard, asking them to return the units if they are not returned within 4 weeks after the end of data collection.
| Self-reported questionnaires
All participants will be asked to complete a self-report questionnaire at two time points: at baseline and at 12 weeks post-randomization.
Participants will return the questionnaires to the research centre in pre-paid envelopes. To maximize response rates to the follow-up questionnaire, participants will receive a reminder telephone call and then sent a reminder postcard if it is not returned within 2 weeks. If the follow-up questionnaire is not received following these reminders, participants will receive a telephone call to ask them to provide a minimum dataset over the telephone (see Table 1 ).
The baseline questionnaire will collect information on participant characteristics (e.g. gender, age, pain sites, co-morbidity, employment status). Questionnaire measures (at baseline and 12-week follow-up) of physical functioning and mental health (The EQ-5D-5L) (Herdman et al., 2011) , pain intensity (Numerical Rating Scale) (Ostelo & de Vet, 2005) , pain location (pain manikin) (Lacey et al., 2014) , physical activity (International Physical Activity Questionnaire for the Elderly (Hurtig-Wennlo, Hagströmer, & Olsson, 2010) and the Self-Efficacy for Exercise Scale (Resnick & Jenkins, 2000) will be collected.
The 12-week follow-up questionnaire will also collect information on any adverse events experienced during the trial, and include a modified version of the treatment acceptability and credibility measure developed by Borkovec and Nau (1972) , with four items each measured using a 10-point scale. This measure will help us to investigate the acceptability and credibility of the HCA-supported iPOPP intervention to older people with chronic MSK pain, by assessing how logical it seems to participants, how confident participants are that it will be successful in managing chronic pain, how confident participants would be in recommending it to a friend and how successful participants feel it would be for another pain problem. Table 1 summarizes all data collection methods and their respective time points.
| Individual CRFs
The CRFs will be audited by the study team during the intervention delivery phase, to ensure that the HCA-supported iPOPP intervention is being delivered per protocol and to identify any further training requirements. The CRFs will also be examined at the end of the pilot trial, to help to assess the fidelity of the iPOPP intervention delivery.
| PILOT TRIAL SUCCESS CRITERIA
The following criteria will be used to judge the success of the pilot trial, in order to make decisions about a future full-scale trial:
1. Satisfactory treatment acceptability and credibility scores at follow-up, whereby the mean score for participants randomized to the HCA-supported intervention should be at least 5 to progress to a full trial.
2. Recruitment rates of at least 70% predicted (n = 150).
3. Follow-up rates of at least 70% of those randomized at the 12-week follow-up.
4. An acceptable intervention adherence rate (at least 50% of those receiving the HCA-supported iPOPP intervention will complete the two consultations).
| SAMPLE SIZE
This is a pilot trial, and a formal sample size calculation is not appropriate.
However, for pilot studies it has been recommended that the dataset should comprise a minimum of 30 participants in each arm (Shih, Ohman-Strickland, & Lin, 2004) . We anticipate that the combined total loss to follow-up and non-adherence to the iPOPP intervention will be no more than 30% at the 12-week follow-up (i.e. 20% due to loss to follow-up and 10% due to non-compliance) and therefore aim to recruit 50 participants in each arm, to account for potential missing data. Part of the rationale of a pilot is to gather data to inform the design of a full trial; therefore, more robust estimates for non-compliance and loss to followup rates in this patient group will be generated by the end of the pilot study and will inform power calculations for a potential full trial.
To determine the number of persons to be mailed the chronic pain screening survey, to identify the 150 participants for this pilot trial, as a guide, we have used data from previous RCTs and observational studies with older adults with MSK pain (e.g. the Self-Management in OA of the Hand [SMOOTH] trial (Dziedzic et al., 2011) , benefits of effective exercise for knee pain (BEEP) trial (Foster et al., 2014) ). To obtain at least 150 eligible adult participants aged 65 and over, we will target at least 800 adults aged 65 and over who have consulted their GP for MSK pain in the index sites in the last 12 months. Based on previous trials, we anticipate that approximately 400 will respond with a completed questionnaire, of whom 150 will fulfil eligibility criteria and consent to participate in the trial, and approximately 105 will provide 12-week follow-up data. Four typical general practice sizes in excess of 7,000 should provide a sufficient sampling frame from which to ascertain the required numbers for this pilot trial. 
| MONITORING AND SAFETY CONSIDERATIONS
The iPOPP pilot trial will be monitored in line with the protocol and Keele CTU standard operating procedures. An independent trial steering committee will monitor the progress of the trial and a data monitoring committee will be convened to monitor the safety of participants and data integrity. Monitoring will also be undertaken by the research ethics committee and the funder (Arthritis Research UK)
in the format of annual progress reports.
All HCAs at participating general practices must report any significant events that they become aware of that occur during the 12-week period over which a patient is participating in the trial (i.e.
12 weeks from the date of randomization). All participants will also be provided with the contact details of the trial coordinator and asked to self-report any such events to the trial team as soon as possible.
Participants randomized to the HCA-supported iPOPP intervention will see or speak to an HCA at the first and second consultation. HCAs will ask participants about, record and report any significant events that they become aware of to the trial team. As the risk of related unexpected serious adverse events (SAEs) is low in this study, HCAs will not be trained in SAE definitions. They should instead report significant events -for example, a participant needing to be admitted to hospital, a fall or any problem which needed medical treatment to prevent the participant being admitted to hospital. Safety reporting procedures will be covered during HCA training sessions, and a copy of the procedure will be filed in the site file. We will also ask participants in their 12-week follow-up questionnaire if they perceive that they have experienced any adverse events during the trial period.
If a potential SAE is reported to a member of the trial team, this information will be passed to the study coordinator at Keele CTU, who will ensure that the necessary paperwork is completed and inform the trial chief investigator and trial GP immediately. The trial GP will assess whether any reported SAEs were related to the trial intervention, according to the process laid out in Keele CTU's standard operating procedure. Any unexpected SAEs considered to be related to the trial procedures will be reported to the research ethics committee by the chief investigator within 15 days of becoming aware of the event.
In addition, all related unexpected SAEs will be reported to Keele University (as the trial sponsor), the trial steering committee and the data monitoring committee.
9 | ANALYSIS
| Qualitative data
Researchers from the qualitative team will examine the audio recordings of the iPOPP intervention consultations and use an intervention fidelity checklist specifically developed for the trial to assess whether components of the consultation intended to be included, and focused on during training, were demonstrated by the HCA.
The interviews with HCAs and trial participants will be transcribed and the data analysed by members of the study team, adopting a constant comparison approach (Glaser, 1965; Hallberg, 2006) , with initial coding of text segments, followed by re-coding and memo writing in order to generate conceptual themes. The study team will then discuss and agree on overarching thematic interpretations. A framework approach will then be used to facilitate interpretation of the data (Richie & Spencer, 1994) . Analysis will be conducted by researchers from different professional backgrounds, to improve the trustworthiness of the analysis (Henwood & Pigeon, 1992) . Following initial inductive analysis, themes will be mapped to behavioural theory by using the Theoretical Domains Framework (Atkins et al., 2017; Michie et al., 2005) to identify influences on behaviour that have an impact on implementation of the iPOPP intervention.
| Quantitative data
The analysis of the quantitative data will be exploratory and provide further data on the feasibility and acceptability of the HCA-supported intervention, and the design and methods of a full-scale RCT. For example, findings from the pilot trial might inform required changes in the trial recruitment processes, data collection processes and outcome measures Participant characteristics (e.g. gender, age, pain sites, co-morbidity, employment status), self-reported at baseline, will be compared by intervention arm and by general practice to explore the balance of patient characteristics. These data will also allow any evidence of selection bias to be assessed by comparing consenting and non-consenting individuals, withdrawals, drop-outs and completers. The percentage of participants consenting to take part in the trial and follow-up rates for the post-intervention follow-up questionnaire per intervention group will also be examined.
Completion rates of the self-reported outcome measures will be reported, to identify any that are poorly completed. The content of the self-reported questionnaire for a full RCT will be adapted accordingly.
Data from the pilot study will also be used to help to inform a sample size calculation for the full-scale trial, for the primary outcome of interest (step counts measured using accelerometry). This estimate will be viewed cautiously, however, given that there are only four practices included in the pilot trial. Participants will only be included in this analysis if they have worn the monitor for at least 5 days, for 10 h or more each day. Valid time will be calculated assuming that any consecutive runs of zero count lasting for 60 min or more are counted as "non-wear" (Foster et al., 2014) . For each participant, we will generate the following: average daily step count, and the proportion of time spent sedentary and in light, moderate and vigorous physical activity, using the cut-offs from Lee et al. (2015) and Freedson, Melanson, and Sirard (1998) , and the proportions of people who meet guideline levels of physical activity for older adults will also be calculated (Department of Health, 2011).
| Integrating quantitative and qualitative data and findings
When the analysis of the quantitative and qualitative data is complete, a triangulation protocol (O'Cathain, Murphy, & Nicholl, 2010;
Tonkin-Crine et al., 2016) will be used. This technique enables integration of data in order to investigate the completeness, convergence and dissonance of key themes across datasets (Farmer, Robinson, Elliott, & Eyles, 2006) . Methods include following a thread and development of a convergence coding matrix. The matrix allows findings from different study components to be displayed side by side. Integration will aid interpretation of findings and inform decisions about changes to trial processes or intervention components ahead of a full-scale trial.
| PATIENT AND PUBLIC INVOLVEMENT AND ENGAGEMENT (PPIE)
The pilot trial design and processes have been informed by patient and public involvement, in line with our centre's strong commitment to involving the public in research (Jinks, Carter, et al., 2016) , following 
| ETHICS AND DISSEMINATION
The pilot trial has been approved by the West Midlands -Solihull
Research Ethics Committee (REC reference: 15/WM/0329).
All participating general practices will receive a poster at the end of the study, which they can display in order to inform participants of the pilot trial results. In addition, all participants will be informed of the results personally by post. The results of this study will be reported to the trial steering committee, data monitoring committee and our funder, published in relevant high-quality peer-reviewed journals and presented at national and international conferences.
| TRIAL MONITORING
The trial steering committee met prior to ethics application in order to agree the final protocol, and at agreed time intervals over the course of the pilot trial. The data monitoring committee also reviewed the study protocol and receive reports at agreed intervals. All data collection, database design, data input and cleaning, as well as trial oversight procedures, will be in line with the standard operating procedures of the Keele CTU and the conditions of the grant.
| DATA CONFIDENTIALITY AND ARCHIVING
All pilot trial-related information will be stored securely at the Arthritis Research UK Primary Care Centre at Keele University. Data will be anonymized using coded identification numbers, with the housing of the data and the linking code in separate locations, under password protection. Access to the data will be restricted to individuals involved in audit and analysis. The data from the pilot trial will be archived and made available for future, secondary analysis and data pooling purposes from the Arthritis Research UK Primary Care Centre at Keele University. It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" licence.
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